Medicenna Therapeutics Corp.
MDNAF
$0.7151
-$0.0289-3.88%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.72% | 4.00% | 9.80% | 9.84% | -23.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.19% | 6.06% | 9.75% | 12.07% | -3.93% |
| Operating Income | -8.19% | -6.06% | -9.75% | -12.07% | 3.93% |
| Income Before Tax | -72.86% | -128.92% | -198.13% | -147.31% | -56.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.86% | -128.92% | -198.13% | -147.31% | -56.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.86% | -128.92% | -198.13% | -147.31% | -56.08% |
| EBIT | -8.19% | -6.06% | -9.75% | -12.07% | 3.93% |
| EBITDA | -8.13% | -6.01% | -9.73% | -12.14% | 3.84% |
| EPS Basic | -65.49% | -123.62% | -192.70% | -122.40% | -29.64% |
| Normalized Basic EPS | -65.72% | -124.12% | -193.05% | -122.60% | -29.62% |
| EPS Diluted | -65.49% | -123.62% | -192.70% | -122.40% | -29.64% |
| Normalized Diluted EPS | -65.72% | -124.12% | -193.05% | -122.60% | -29.62% |
| Average Basic Shares Outstanding | 7.06% | 4.05% | 3.73% | 7.60% | 13.72% |
| Average Diluted Shares Outstanding | 7.06% | 4.05% | 3.73% | 7.60% | 13.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
